Molecular advances to treat cancer of the brain

Bibliography

• FATHALLAH-SHAYKH H: New molecular strategies to cure brain tumors. Arch. Neurol. (1999) 56:449–453.
   PubMed Web of Science ®Google Scholar
• ••A thorough review.
   Google Scholar
• FATHALLAH-SHAYKH HM, MCINTIRE DD: Brain tumors in the elderly: undefeated and gaining grounds. Arch. Neurol. (1998) 55:905–906.
   PubMed Web of Science ®Google Scholar
• ••An editorial on the rising trends of malignant gliomas in theelderly.
   Google Scholar
• RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retrovirus-producing cells. Nature Med. (1997) 3:1354–1361.
   PubMed Web of Science ®Google Scholar
• ••A prospective clinical study of retroviral-mediated genetransfer of thymidine kinase for malignant brain tumours.
   Google Scholar
• DEWEY RA, MORRISSEY G, COWSILL CM et al.: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical research. Nature Med. (1999) 5:1256–1263.
   PubMed Web of Science ®Google Scholar
• ••A study of the adverse effects of adenoviral vectors in thebrain.
   Google Scholar
• FATHALLAH-SHAYKH HM, ZHAO 41, KAFROUNI Al, SMITH GM, FORMAN J: Gene transfer of IFN-y into established brain tumors represses growth by antiangiogenesis. J. Immunol. (2000) 164:217–222.
   PubMed Web of Science ®Google Scholar
• ••A study of the efficacy of adenoviral-mediated gene transferof IFN-y and the pathogenesis of the antitumour response.
   Google Scholar
• FATHALLAH-SHAYKH HM, KAFROUNI Al, ZHAO 41, SMITH GM, FORMAN J: Gene transfer into brain parenchyma elicits antitumor effects. Cancer Res. (2000) 60:1797–1799.
   PubMed Web of Science ®Google Scholar
• •A study looking at specificity of adenoviral-mediated gene transfer into the brain.
   Google Scholar
• PARKS RJ, CHEN L, ANTON M, SANKAR U, DUDNICK MA, GRAHAM FL: A helper-dependent adenovirus vector system: removal of a helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA (1996) 93:13565–13570.
   PubMed Web of Science ®Google Scholar
• ••A study introducing the concept of helper dependentadenoviruses.
   Google Scholar
• YANG Y, NUNES FA, BERENCSI K, FURTH EE, GONCZOL E, WILSON JM: Cellular Immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA (1994) 91:4407–4411.
   PubMed Web of Science ®Google Scholar
• •A study on cellular immunity against El-deleted adenoviral vectors.
   Google Scholar
• MORSY MA, GU MC, MOTZEL S et al.: An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA (1998) 95:7866–7871.
   PubMed Web of Science ®Google Scholar
• •A study of the efficacy of gutless adenovirus.
   Google Scholar
• IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nature Med. (1999) 5:881–887.
   PubMed Web of Science ®Google Scholar
• ••A study of the effects of cyclophosphamide on gene transferinto brain tumours after systemic administration of adenovirus. 9:
   Google Scholar
• PENNISI E: Training viruses to attack cancer. Science (1998) 282:1244-1246. News report on oncolytic viruses.
   Google Scholar
• HALL AR, Da BR, O'CARROLL SJ, BRAITHWAITE AW: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Med. (1998) 4:1068-1072. A study refuting the basic concept of adenoviral oncolytic therapy.
   Google Scholar
• KIRN D, HERMISTON T, MCCORMICK F: ONYX-015: Clinical data are encouraging. Nature Med. (1998) 4:1341-1342.News report on an oncolytic adenovirus.
   Google Scholar
• BUCKLEY CD, PILLING D, HENRIQUEZ NV et al.: RGD peptides induce apoptosis by direct caspase-3 activa-tion. Nature (1999) 397:534-539. A study of the mechanism of action of RGD peptides.
   Google Scholar
• ELLERBY HM, ARAP W, ELLERBY LM et al.: Anti-cancer activity of targeted pro-apoptotic peptides. Nature Med. (1999) 5:1032–1038.
   PubMed Web of Science ®Google Scholar
• ••A study of the efficacy of peptides combining targeteddelivery to apoptotic domains.
   Google Scholar
• HAHN WC, STEWART SA, BROOKS SA et al.: Inhibition of telomerase limits the growth of human cancer cells. Nature Med. (1999) 5:1164–1170.
   PubMed Web of Science ®Google Scholar
• ••A study of the efficacy of expressing a dominant negativetelomerase.
   Google Scholar
• GOLUB TR, SLONIM DK, TAMAYO P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 286:531–537.
   PubMed Web of Science ®Google Scholar
• ••A study of the applicability of gene microarray technology toclassification of human leukaemia and predicting treatment outcome.
   Google Scholar
• HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994–1998.
   PubMed Web of Science ®Google Scholar
• ••A study proposing novel phases of tumour growth inrelation to angiogenesis.
   Google Scholar
• BARINAGA M: New type of blood vessels found in tumors. Science (1999) 285:1475.
   PubMed Web of Science ®Google Scholar
• •New report that tumour cells themselves make blood vessels.
   Google Scholar
• MANIOTIS AJ, FOLBERG R, HESS A et al.: Vascular channels formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Path. (1999) 155:739–752.
   PubMed Web of Science ®Google Scholar
• ••A study reporting that tumour cells themselves make bloodvessels.
   Google Scholar
• BISSELL MJ: Tumor Plasticity allows vascular mimicry, a novel form of angiogenic switch. Am. J. Path. (1999) 155:675–679.
   PubMed Web of Science ®Google Scholar
• ••An editorial on the paper showing that tumour cellsthemselves make blood vessels.
   Google Scholar
• BARINAGA M: A face-off over tumor blood supply. Science (2000) 287:784–785.
   Google Scholar
• •News report on the controversy that tumour cells themselves make blood vessels.
   Google Scholar
• LASSAR AB, SKAPEK SX, NOVITCH B: Regulatory mechanisms that coordinate skeletal muscle differen-tiation and cell cycle withdrawal. Curr. Opin. Cell Biol. (1994) 6:788–794.
   PubMed Web of Science ®Google Scholar
• •A review on basic helix-loop-helix transcription factors.
   Google Scholar
• LYDEN D, YOUNG AZ, ZAGZAG D et al.: Idl and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 401:670–677.
   PubMed Web of Science ®Google Scholar
• ••A study of the Idl and Id3 knockout mice.
   Google Scholar
• FATHALLAH-SHAYKH HM, GAO W, CHO M, HERRERA MA: Priming in the brain, an immunologically-privileged organ, elicits anti-tumor immunity. Int. J. Cancer (1998) 75:266–276.
   PubMed Web of Science ®Google Scholar
• ••A study of the antitumour effects of IFN-y-secretingmalignant gliomas.
   Google Scholar
• DE VISSER KE, KAST WM: Effects of TGF-f3 on the immune system: implications for cancer immuno-therapy. Leukemia (1999) 13:1188–1199.
   PubMed Web of Science ®Google Scholar
• •A review of the immunosuppressive effects of TGF-I3.
   Google Scholar
• WOJTOWICS-PRAGA S: Reversal of tumor-induced immunosuppression; a new approach to cancer therapy. J. Immunother. (1997) 20:165–177.
   PubMed Web of Science ®Google Scholar
• •A review of the immunosuppressive effects of TGF-I3.
   Google Scholar
• STRAND S, HOFMANN WJ, HUG H et al.: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Med. (1996) 2:1361-1366.
   Google Scholar
• ••A study of the evasiveness of Fas ligand-expressingmalignant cells.
   Google Scholar
• O'CONNELL J, BENNETT MW, O'SULLIVAN GC, COLLINS JK, SHANAHAN F: Fas counter-attack-the best form of tumor defense? Nature Med. (1999) 5:267–268.
   Google Scholar
• •An editorial on the evasiveness of Fas ligand-expressing malignant cells.
   Google Scholar
• GIMMI CD, MORRISON BW, MAINPICE BA et al.: Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. (1996) 2:1367–1370.
   PubMed Web of Science ®Google Scholar
• •A study of the immunosuppressive effects of mucins.
   Google Scholar
• Prrn RM, MARSTERS SA, LAWRENCE DA et al.: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 396:699–703.
   PubMed Web of Science ®Google Scholar
• ••A study of a decoy receptor for Fas ligand.
   Google Scholar
• BOSSI G, GRIFFITHS GM: Degranulation plays an essential role in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med. (1999) 5:90–95.
   PubMed Web of Science ®Google Scholar
• ••A study to localise Fas ligand in activated T-cells.
   Google Scholar
• NAKASHIMA M, SONODA K, WATANABE T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nature Med. (1999) 5:938–942.
   PubMed Web of Science ®Google Scholar
• ••A study of the effects of RCAS1 on T-cells.
   Google Scholar
• MOREL S, LEVY F, BURLET-SCILTZ O, et al.: Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 12:107–117.
   Google Scholar
• ••A study comparing antigen processing by the standard andimmunoproteasomes.
   Google Scholar
• MANGENEY M, HEIDMANN T: Tumor cells expressing a retroviral envelope escape immune rejection in vivo. Proc. Natl. Acad. Sci. USA (1998) 95:14290–1925.
   PubMedGoogle Scholar
• ••A study of the immunological effects of retroviral envelopproteins.
   Google Scholar
• RIDGE JP, DI ROSA F, MATZINGER P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature (1998) 393:474–478.
   PubMed Web of Science ®Google Scholar
• ••A study of the role of CD40 molecule in mediating TH cellfunction.
   Google Scholar
• BENNETT SRM, CARBONE FR, KARAMALIS F, FLAVELL RA, MILLER JFAP, HEATH WR: Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature (1998) 393:478–483.
   PubMed Web of Science ®Google Scholar
• ••A study of the role of CD40 molecule in mediating TH cellfunction.
   Google Scholar
• HERMANS IF, RITCHIE DS, DAISH A, YANG J, KEHRY MR, RONCHESE F: Impaired ability of MHC class dendritic cells to provide tumor protection is rescued by CD40 ligation. J. Immunol. (1999) 163:77–81.
   PubMed Web of Science ®Google Scholar
• ••A study of the role of CD40 molecule in mediating TH cellfunction.
   Google Scholar
• SOTOMAYOR EM, BORRELLO I, TUBB E et al.: Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nature Med. (1999) 5:780–787.
   PubMed Web of Science ®Google Scholar
• ••A study of CD40 signalling in reversing tumour tolerance.
   Google Scholar
• DIEHL L, DEN BOER AT, SCHOENBERGER SP et al.: CD40 activation in vivo overcomes peptide-induced periph-eral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med. (1999) 5:774–779.
   PubMed Web of Science ®Google Scholar
• ••A study of CD40 signalling in reversing tumour tolerance.
   Google Scholar
• KIKUSHI T, CRYSTAL RG: Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther. (1999) 10:1375–1387.
   PubMed Web of Science ®Google Scholar
• ••A study of gene transfer of CD40 ligand for treating experi-mental cancer.
   Google Scholar
• FISHER GH, ORSULIC S, HOLLAND E et al.: Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene (1999) 18:5253–5260.
   PubMed Web of Science ®Google Scholar
• ••A study to develop models of human cancer by an avianretroviral virus in transgenic mice.
   Google Scholar
• MARSHALL E: FDA halts all gene therapy trials at Penn. Science (2000) 287:565–566.
   PubMed Web of Science ®Google Scholar
• •News report on the unfortunate death of a patient treated by gene therapy.
   Google Scholar
• DICKMAN S: Antibodies stage a comeback in cancer treatment. Science (1998) 280:1196–1197.
   PubMed Web of Science ®Google Scholar
• ••News report on the history of antibodies in the treatment ofcancer.
   Google Scholar